Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest Medicago Inc. Stories

2013-09-18 08:28:52

OSAKA, Japan and QUEBEC CITY, Canada, Sept. 18, 2013 /PRNewswire/ - Mitsubishi Tanabe Pharma Corporation (TSE: 4508) ("Mitsubishi Tanabe Pharma" or "MTPC") and Medicago Inc. (TSX: MDG) announced today the completion of the previously announced acquisition of Medicago Inc. by MTPC. On September 18, 2013, 9284-9686 Québec Inc.,a subsidiary of MTPC, acquired all of the outstanding common shares of Medicago, other than the common shares currently held by MTPC and Philip Morris...

2013-09-12 08:30:10

QUEBEC CITY, Sept. 12, 2013 /PRNewswire/ - Medicago Inc. (TSX: MDG; OTCQX: MDCGF) ("Medicago" or the "Company"), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), is pleased to announce that the Superior Court of Quebec has granted its final order approving the previously announced plan of arrangement (the "Arrangement") involving the Company, Mitsubishi Tanabe...

2013-08-29 16:24:55

QUEBEC CITY, Aug. 29, 2013 /PRNewswire/ - Medicago Inc. (TSX: MDG; OTCQX: MDCGF) ("Medicago" or the "Company"), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), during today's special meeting of shareholders of Medicago (the "Meeting"), is pleased to annouce that its shareholders have approved the resolution authorizing the previously announced plan of...

2013-08-19 08:27:57

QUEBEC CITY, Aug. 19, 2013 /PRNewswire/ - Medicago Inc. (TSX: MDG; OTCQX: MDCGF) ("Medicago"), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), announced today that Institutional Shareholder Services, Inc. ("ISS") and Glass, Lewis & Co., LLC ("Glass Lewis"), two leading independent proxy firms have both recommended that Medicago shareholders vote FOR the...

2013-08-09 16:22:47

QUEBEC CITY, Aug. 9, 2013 /PRNewswire/ - Medicago Inc. (TSX: MDG), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced its operational and financial results for the second quarter ended June 30, 2013. The Company's financial statements and management report are available at www.sedar.com and at www.medicago.com. Financial Results For the...

2013-07-31 20:21:40

QUEBEC CITY, July 31, 2013 /PRNewswire/ - Medicago Inc. (TSX: MDG; OTCQX: MDCGF) ("Medicago"), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), announced today that it has obtained on July 25, 2013 an interim order from the Superior Court of Québec (the "Interim Order") authorizing, among other things, Medicago to hold a special meeting (the "Meeting") of...

2013-07-12 04:21:22

QUÉBEC CITY, July 12, 2013 /PRNewswire/ - Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), announced today that it has entered into a definitive arrangement agreement with Mitsubishi Tanabe Pharma Corporation ("Mitsubishi Tanabe Pharma" or "MTPC") whereby MTPC will acquire all of the issued and outstanding common...

2013-06-27 16:25:22

SEATTLE and QUEBEC CITY, June 27, 2013 /PRNewswire/ - Immune Design, a leader in the field of therapeutic vaccines for cancer, infectious diseases and allergy, and Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that they have entered a license agreement providing Medicago the use and commercialization...

2013-06-20 08:26:11

-First successful plant-based Rotavirus VLP containing all 4 Major proteins--International Patent Application filed- QUEBEC CITY, June 20, 2013 /PRNewswire/ - Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced the successful production of a Rotavirus VLP vaccine candidate comprising all four structural...

2013-06-17 08:27:46

QUEBEC CITY, June 17, 2013 /PRNewswire/ - Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), announced today it was granted a patent from the European Patent Office (EPO) providing Medicago the exclusive rights to produce influenza VLPs in plants. Patent Number 2173886, titled "Influenza virus-like particles (VLPs) comprising...